Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07455058 · ClinicalTrials.gov registry record
Water Vapor Ablation for Prostate Cancer: Long-Term Registry
A clinical trial, sponsored by Francis Medical.
- Recruiting
- Registry status
- 2,500
- Enrollment target
NCT07455058: Recruiting study, sponsored by Francis Medical.
NCT07455058 is a clinical trial that is actively recruiting participants, run by Francis Medical. The registered enrollment target is 2,500 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07455058 is actively recruiting participants, sponsored by Francis Medical.
- RECRUITING
- Registry status
- 2,500 participants
- Enrollment target
Study Summary
The purpose of the registry is to evaluate real-world safety, efficacy, and patient reported outcomes among participants receiving Vanquish Water Vapor Ablation System therapy (Vanquish Therapy). This includes longitudinal assessment of patients who have received or will receive the therapy one or multiple times as part of routine clinical care and encompasses those who completed a company-sponsored Vanquish therapy study (as applicable).
Primary Outcome
Freedom from disease specific mortality.
Interventions
- DEVICE Vanquish Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,500 participants |
| Start Date | 2026-06-05 |
| Est. Completion | 2041-07-31 |
What NCT07455058 shows while recruiting
NCT07455058 is an observational study that tracks outcomes without assigning an intervention. Its 2,500 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Vanquish Therapy is the first listed.
NCT07455058 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07455058 about?
NCT07455058 is a clinical study titled "Water Vapor Ablation for Prostate Cancer: Long-Term Registry". The purpose of the registry is to evaluate real-world safety, efficacy, and patient reported outcomes among participants receiving Vanquish Water Vapor Ablation System therapy (Vanquish Therapy). This includes longitudinal assessment of patients who have received or will receive the therapy one or m...
What is the current status of trial NCT07455058?
This trial is currently recruiting. The enrollment target is 2,500 participants. The study started on 2026-06-05. Estimated completion is 2041-07-31.
What interventions are being tested in trial NCT07455058?
The interventions under investigation include: Vanquish Therapy (DEVICE).
Who is sponsoring clinical trial NCT07455058?
This trial is sponsored by Francis Medical, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001160 · 2,500 participants
Studies on Tumors of the Thyroid
- NCT01904188 · 2,500 participants
Clinical Microbial Species & Antibiotic Resistance ID in ED Patients Presenting With Infection - is Rapid ID Possible & Accurate?
- NCT02257229 · 2,500 participants
Prospective Evaluation of Treatment for Clubfoot
- NCT02530658 · 2,500 participants
Next Generation Sequencing of Normal Tissues Prospectively in Pediatric Oncology Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI